192 related articles for article (PubMed ID: 19172517)
1. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.
Nomura S; Inami N; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Urase F; Maeda Y; Ohtani H; Iwasaka T
Platelets; 2009 Feb; 20(1):16-22. PubMed ID: 19172517
[TBL] [Abstract][Full Text] [Related]
2. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Inami N; Tanaka A; Nanba M; Shouda Y; Takahashi N; Kimura Y; Iwasaka T
Thromb Res; 2008; 122(1):39-45. PubMed ID: 17920663
[TBL] [Abstract][Full Text] [Related]
3. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
Nomura S; Shouzu A; Omoto S; Inami N; Shimazu T; Satoh D; Kajiura T; Yamada K; Urase F; Maeda Y; Iwasaka T
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):440-7. PubMed ID: 19525846
[TBL] [Abstract][Full Text] [Related]
4. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
Nomura S; Taniura T; Shouzu A; Omoto S; Suzuki M; Okuda Y; Ito T
Vasc Health Risk Manag; 2018; 14():225-232. PubMed ID: 30271161
[TBL] [Abstract][Full Text] [Related]
5. Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
Inami N; Nomura S; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Nanba M; Shouda Y; Iwasaka T
Pathophysiol Haemost Thromb; 2007; 36(1):1-8. PubMed ID: 18332608
[TBL] [Abstract][Full Text] [Related]
6. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients.
Shimazu T; Inami N; Satoh D; Kajiura T; Yamada K; Iwasaka T; Nomura S
J Thromb Thrombolysis; 2009 Nov; 28(4):429-35. PubMed ID: 19137265
[TBL] [Abstract][Full Text] [Related]
7. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.
Nomura S; Shouzu A; Omoto S; Inami N; Ueba T; Urase F; Maeda Y
J Atheroscler Thromb; 2009 Apr; 16(2):83-90. PubMed ID: 19403992
[TBL] [Abstract][Full Text] [Related]
8. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.
Nomura S; Taniura T; Shouzu A; Omoto S; Inami N; Fujita S; Tamaki T; Yokoi T; Shimizu T; Ito T
Int J Gen Med; 2012; 5():535-40. PubMed ID: 22807641
[TBL] [Abstract][Full Text] [Related]
9. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
10. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus.
Nomura S; Omoto S; Yokoi T; Fujita S; Ozasa R; Eguchi N; Shouzu A
Int J Gen Med; 2011; 4():539-45. PubMed ID: 21845063
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin: clinical effects from the LIVES Study.
Teramoto T
Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
[TBL] [Abstract][Full Text] [Related]
12. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
13. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T; Fukuhara S
Clin Appl Thromb Hemost; 2004 Jul; 10(3):205-15. PubMed ID: 15247977
[TBL] [Abstract][Full Text] [Related]
14. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Diabetes Complications; 2003; 17(3):153-9. PubMed ID: 12738400
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.
Huang CH; Huang YY; Hsu BR
J Diabetes Investig; 2016 Sep; 7(5):769-76. PubMed ID: 27181110
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin and carbohydrate metabolism: what is the evidence?
Filippatos TD; Elisaf MS
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):955-60. PubMed ID: 26967972
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
18. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study.
Matsubara T; Naruse K; Arakawa T; Nakao M; Yokoi K; Oguri M; Marui N; Amano T; Ichimiya S; Ohashi T; Imai K; Sakai S; Sugiyama S; Ishii H; Murohara T
J Cardiol; 2012 Nov; 60(5):389-94. PubMed ID: 22884685
[TBL] [Abstract][Full Text] [Related]
19. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Nomura S; Takahashi N; Inami N; Kajiura T; Yamada K; Nakamori H; Tsuda N
Atherosclerosis; 2004 Jun; 174(2):329-35. PubMed ID: 15136063
[TBL] [Abstract][Full Text] [Related]
20. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
Arnaboldi L; Corsini A
Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
